Portola Pharmaceuticals to Present New Interim Phase 2 Data for Cerdulatinib at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

Stacey Gandler
Brand Nourishment

Matthew Durham
Omnidynamic Marketing

Amy Giles
Increasing Engagement

Frank Burrell
Scientific Storytelling

Pat Purcell
Meeting Engagement

David Linetsky
Point-of-Care Marketing

Liz Kane
Impactful Strategy

Matt Turner
Patient Affordability

Brenda Snow
Authentic Patient Voice

Bud Bilanich
Success Coach

Paul Theisen
Patient Acquisition

Daniel Sontupe
Market Access

Suma Ramadas, PhD
Medical Affairs

Joey Cohen
Medication Adherence